Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 2.7 %

CHEK opened at $0.83 on Tuesday. Check-Cap has a 52-week low of $0.76 and a 52-week high of $3.45. The company has a 50 day moving average of $1.13 and a two-hundred day moving average of $1.69. The company has a market cap of $4.83 million, a P/E ratio of -0.28 and a beta of 0.25.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.